n-CoDeR concept: unique types of antibodies for diagnostic use and therapy

References

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495.497 (1975).
   Web of Science ®Google Scholar
• Griffiths AD, Williams SC Hartley O et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13(14), 3245.3260 (1994).
   Web of Science ®Google Scholar
• An interesting technology to create large antibody gene repertoires.
   Google Scholar
• Vaughan TJ, Williams AJ, Pritchard K et al. Human antibodies with sub-nanomolar affinities isolated from a large nonimmunized phage display library. Nature Biotechnol. 14(3), 309.314 (1996).
   Google Scholar
• Sheets MD, Amersdorfer P, Finnern R et al. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc. Natl Acad. Sci. USA 95(11), 6157.6162 (1998).
   Google Scholar
• de Haard HJ, van Neer N, Reurs A et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274(26), 18218. 18230 (1999).
   Google Scholar
• Knappik A, Ge L, Honegger A et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296(1), 57.86 (2000).
   Google Scholar
• An elegant technology to create synthetic antibody libraries.
   Google Scholar
• Soderlind E, Strandberg L, Jirholt P et al. Recombining germline-derived CDR sequences for creating diverse singleframework antibody libraries. Nature Biotechnol. 18(8), 852.856 (2000).
   Google Scholar
• A totally new concept of the creation of highly functional antibody repertoires.
   Google Scholar
• de Wildt RM, Mundy CR, Gorick BD, Tomlinson IM. Antibody arrays for highthroughput screening of antibody-antigen interactions. Nature Biotechnol. 18(9), 989). 994 (2000).
   Google Scholar
• An interesting methodology for the rapid identification of reactive clones from antibody gene repertoires.
   Google Scholar
• Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature 352(6336), 624.628 (1991).
   Web of Science ®Google Scholar
• The first example of selection from antibody gene repertoires using phage display.
   Google Scholar
• Barbas CF 3rd, Bain JD, Hoekstra DM, Lerner RA. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl Acad. Sci. USA 89(10), 4457.4461 (1992).
   Google Scholar
• An interesting way for the introduction of synthetic genetic variation in antibody gene repertoires.
   Google Scholar
• de Kruif J, Boel E, Logtenberg T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol. 248(1), 97.105 (1995).
   Google Scholar
• Braunagel M, Little M. Construction of a semisynthetic antibody library using trinucleotide oligos. Nucleic Acids Res. 25(22), 4690.4691 (1997).
   Google Scholar
• Jirholt P, Ohlin M, Borrebaeck CAK, Soderlind E. Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework. Gene 215(2), 471.476 (1998).
   Web of Science ®Google Scholar
• The principle behind n-CoDeR is presented.
   Google Scholar
• MacCallum RM, Martin AC, Thornton JM. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol. 262(5), 732. 745 (1996).
   Google Scholar
• Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc. Natl Acad. Sci. USA 91(11), 5022.5026 (1994).
   Google Scholar
• Ramsay G. DNA chips: state-of-the art. Nature Biotechnol. 16(1), 40.44 (1998).
   Google Scholar
• Presentation of the DNA chip.
   Google Scholar
• Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503.511 (2000).
   Web of Science ®Google Scholar
• Bustin SA. eLymphochipsf and cancer profiles. Mol. Med. Today 6(6), 218 (2000).
   Google Scholar
• Lossos IS, Alizadeh AA, Eisen MB et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc. Natl Acad. Sci. USA 97(18), 10209.10213 (2000).
   Google Scholar
• Nacht M, Ferguson AT, Zhang W et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res. 59(21), 5464). 5470 (1999).
   Google Scholar
• Martin KJ, Kritzman BM, Price LM et al. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res. 60(8), 2232.2238 (2000).
   Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747.752 (2000).
   Web of Science ®Google Scholar
• Borrebaeck CAK. Antibodies in diagnostics from immunoassays to protein chips. Immunol. Today 21(8), 379.382 (2000).
   Google Scholar
• Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biology (2001) 2(2) http://www.genomebiology.com/2001/2/2/ research/0004/
   Google Scholar
• One of the first results of protein chips with increased complexity.
   Google Scholar
• Karlsson M, Pavlov MY, Malmqvist M, Persson B, Ehrenberg M. Initiation of Escherichia coli ribosomes on matrix coupled mRNAs studied by optical biosensor technique. Biochimie 81(10), 995.1002 (1999).
   PubMed Web of Science ®Google Scholar
• Massuger LF, Thomas CM, Segers MF et al. Specific and nonspecific immunoassays to detect HAMA after administration of indium-111-labeled OV-TL 3 F(ab)2 monoclonal antibody to patients with ovarian cancer. J. Nucl. Med. 33(11), 1958. 1963 (1992).
   Google Scholar
• Cheung NK, Cheung IY, Canete A et al. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res. 54(8), 2228. 2233 (1994).
   Google Scholar
• Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1(4), 365.372 (1994).
   Google Scholar
• De Nardo GL, Kroger LA, Mirick GR, Lamborn KR, De Nardo SJ. Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1. Int. J. Biol. Markers 10(2), 67.74 (1995).
   Google Scholar
• Yuan F, Dellian M, Fukumura D et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55(17), 3752–3756 (1995).
   Google Scholar
• Genentech, Inc. US4816567 (1989).
   Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature (1988) 332(6162), 323–327.
   Web of Science ®Google Scholar
• Queen C, Schneider WP, Selick HE et al. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl Acad. Sci. USA 86(24), 10029–10033 (1989).
   Google Scholar
• Daugherty BL, DeMartino JA, Law MF, Kawka DW, Singer II, Mark GE. Polymerase chain reaction facilitates the cloning, CDR-grafting and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins. Nucleic Acids Res. 19(9), 2471–2476 (1991).
   Google Scholar
• Eclagen Ltd. WO9859244 (1998).
   Google Scholar
• • Interesting analysis method for T-cell epitope frequency.
   Google Scholar
• Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228(4705), 1315–1317 (1985).
   Web of Science ®Google Scholar
• McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348(6301), 552–554 (1990).
   Web of Science ®Google Scholar
• Jakobovits A, Moore AL, Green LL et al. Germ-line transmission and expression of a human-derived yeast artificial chromosome. Nature 362(6417), 255–258 (1993).
   Web of Science ®Google Scholar
• • Transgenic mouse technology.
   Google Scholar
• Lonberg N, Taylor LD, Harding FA et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368(6474), 856–859 (1994).
   Web of Science ®Google Scholar
• • Transgenic mouse technology.
   Google Scholar
• Ishida I, Yoshida H, Tomizuka K. Production of a diverse repertoire of human antibodies in genetically engineered mice. Microbiol. Immunol. 42(3), 143–150 (1998).
   Google Scholar
• • Transgenic mouse technology.
   Google Scholar
• Lener M, Horn IR, Cardinale A et al. Diverting a protein from its cellular location by intracellular antibodies. The case of p21Ras. Eur. J. Biochem. 267(4), 1196–1205 (2000).
   Google Scholar
• Poznansky MC, La Vecchio J, Silva-Arietta S et al. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus Type 1 Tat. Hum. Gene. Ther. 10(15), 2505–2514 (1999).
   Google Scholar
• Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol. Today 21(8), 403–410 (2000).
   Google Scholar
• Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anticancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkins B-cell lymphoma. Biochem. Soc. Trans. 25(2), 705–708 (1997).
   Google Scholar
• Grillo-Lopez AJ, White CA, Varns C et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin. Oncol. 26(5 Suppl. 14), 66–7M3 (1999).
   Google Scholar
• Johnson TA, Press OW. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann. Hematol. 79(4), 175–182 (2000).
   Web of Science ®Google Scholar
• Vose JM, Colcher D, Gobar L et al. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkins lymphoma. Leuk. Lymphoma. 38(1–2), 91–101 (2000). 48 Messmann RA, Vitetta ES, Headlee D et al. A Phase I study of combination therapy with immunotoxins IgG-HD37- deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin. Cancer Res. 6(4), 1302– 1313 (2000).
   Google Scholar
• Cochlovius B, Kipriyanov SM et al. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. J. Immunol. (2000) 165(2), 888–895.
   Web of Science ®Google Scholar
• Cragg MS, French RR, Glennie MJ. Signaling antibodies in cancer therapy. Curr. Opin. Immunol. 11(5), 541–547 (1999).
   Google Scholar
• Tutt AL, French RR, Illidge TM. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161(6), 3176– 3185 (1998).
   Google Scholar
• Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19 (3),1720–1730 (1999).
   Google Scholar